MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance
Diabetes Metab. 2021 Oct 19:101292. doi: 10.1016/j.diabet.2021.101292. Online ahead of print.ABSTRACTAIM: - MG53 is a myokine modulating insulin signalling in several tissues; its relationship to glucose tolerance or risk of developing type 2 diabetes mellitus (T2DM) is unknown. This observational, prospective study aimed at evaluating the relationship between MG53 and glucose tolerance, testing whether its circulating levels may be associated with disease progression in a cohort at high risk of T2DM.METHODS: - Five hundred and fifteen subjects who underwent a deep characterization of their glucose tolerance in the years 2...
Source: Diabetes and Metabolism - October 22, 2021 Category: Endocrinology Authors: Cristina Bianchi Francesco Raggi Chiara Rossi Simona Frontoni Riccardo C Bonadonna Stefano Del Prato Anna Solini Source Type: research

Insulin pump initiation in outpatient settings: when technology facilitates new healthcare organizations
Diabetes Metab. 2021 Oct 18:101290. doi: 10.1016/j.diabet.2021.101290. Online ahead of print.NO ABSTRACTPMID:34673241 | PMC:PMC8523025 | DOI:10.1016/j.diabet.2021.101290 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 21, 2021 Category: Endocrinology Authors: Pr Charles Thivolet Source Type: research

Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: a cohort study of 85,609 pregnant women
CONCLUSION: . - We found higher serum UA at 13-18 gestational weeks was a risk factor for GDM. Our findings provide new evidence for the role of serum UA in the prevention and early intervention of GDM, and highlighted the need for monitoring serum UA at 13-18 gestational weeks.PMID:34666165 | DOI:10.1016/j.diabet.2021.101293 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Yan Zhao Yongbo Zhao Kechen Fan Liping Jin Source Type: research

Short course corticosteroid treatment and closed-loop insulin delivery system: the experience of the DBLG1 pre-launch
Diabetes Metab. 2021 Oct 16:101294. doi: 10.1016/j.diabet.2021.101294. Online ahead of print.ABSTRACTNo abstract (brief report).PMID:34666166 | DOI:10.1016/j.diabet.2021.101294 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Coralie Amadou Sylvia Franc Erik Huneker Guillaume Charpentier Alfred Penfornis Source Type: research

The Progressive Uncoupling of Maternal Insulin Clearance and Insulin Sensitivity across Gestation
Diabetes Metab. 2021 Oct 16:101291. doi: 10.1016/j.diabet.2021.101291. Online ahead of print.NO ABSTRACTPMID:34666167 | DOI:10.1016/j.diabet.2021.101291 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Mireille van Poppel Ravi Retnakaran Source Type: research

Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: a cohort study of 85,609 pregnant women
CONCLUSION: . - We found higher serum UA at 13-18 gestational weeks was a risk factor for GDM. Our findings provide new evidence for the role of serum UA in the prevention and early intervention of GDM, and highlighted the need for monitoring serum UA at 13-18 gestational weeks.PMID:34666165 | DOI:10.1016/j.diabet.2021.101293 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Yan Zhao Yongbo Zhao Kechen Fan Liping Jin Source Type: research

Short course corticosteroid treatment and closed-loop insulin delivery system: the experience of the DBLG1 pre-launch
Diabetes Metab. 2021 Oct 16:101294. doi: 10.1016/j.diabet.2021.101294. Online ahead of print.ABSTRACTNo abstract (brief report).PMID:34666166 | DOI:10.1016/j.diabet.2021.101294 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Coralie Amadou Sylvia Franc Erik Huneker Guillaume Charpentier Alfred Penfornis Source Type: research

The Progressive Uncoupling of Maternal Insulin Clearance and Insulin Sensitivity across Gestation
Diabetes Metab. 2021 Oct 16:101291. doi: 10.1016/j.diabet.2021.101291. Online ahead of print.NO ABSTRACTPMID:34666167 | DOI:10.1016/j.diabet.2021.101291 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Mireille van Poppel Ravi Retnakaran Source Type: research

Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: a cohort study of 85,609 pregnant women
CONCLUSION: . - We found higher serum UA at 13-18 gestational weeks was a risk factor for GDM. Our findings provide new evidence for the role of serum UA in the prevention and early intervention of GDM, and highlighted the need for monitoring serum UA at 13-18 gestational weeks.PMID:34666165 | DOI:10.1016/j.diabet.2021.101293 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Yan Zhao Yongbo Zhao Kechen Fan Liping Jin Source Type: research

Short course corticosteroid treatment and closed-loop insulin delivery system: the experience of the DBLG1 pre-launch
Diabetes Metab. 2021 Oct 16:101294. doi: 10.1016/j.diabet.2021.101294. Online ahead of print.ABSTRACTNo abstract (brief report).PMID:34666166 | DOI:10.1016/j.diabet.2021.101294 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Coralie Amadou Sylvia Franc Erik Huneker Guillaume Charpentier Alfred Penfornis Source Type: research

The Progressive Uncoupling of Maternal Insulin Clearance and Insulin Sensitivity across Gestation
Diabetes Metab. 2021 Oct 16:101291. doi: 10.1016/j.diabet.2021.101291. Online ahead of print.NO ABSTRACTPMID:34666167 | DOI:10.1016/j.diabet.2021.101291 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Mireille van Poppel Ravi Retnakaran Source Type: research

Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: a cohort study of 85,609 pregnant women
CONCLUSION: . - We found higher serum UA at 13-18 gestational weeks was a risk factor for GDM. Our findings provide new evidence for the role of serum UA in the prevention and early intervention of GDM, and highlighted the need for monitoring serum UA at 13-18 gestational weeks.PMID:34666165 | DOI:10.1016/j.diabet.2021.101293 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Yan Zhao Yongbo Zhao Kechen Fan Liping Jin Source Type: research

Short course corticosteroid treatment and closed-loop insulin delivery system: the experience of the DBLG1 pre-launch
Diabetes Metab. 2021 Oct 16:101294. doi: 10.1016/j.diabet.2021.101294. Online ahead of print.ABSTRACTNo abstract (brief report).PMID:34666166 | DOI:10.1016/j.diabet.2021.101294 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Coralie Amadou Sylvia Franc Erik Huneker Guillaume Charpentier Alfred Penfornis Source Type: research

The Progressive Uncoupling of Maternal Insulin Clearance and Insulin Sensitivity across Gestation
Diabetes Metab. 2021 Oct 16:101291. doi: 10.1016/j.diabet.2021.101291. Online ahead of print.NO ABSTRACTPMID:34666167 | DOI:10.1016/j.diabet.2021.101291 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Mireille van Poppel Ravi Retnakaran Source Type: research

Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: a cohort study of 85,609 pregnant women
CONCLUSION: . - We found higher serum UA at 13-18 gestational weeks was a risk factor for GDM. Our findings provide new evidence for the role of serum UA in the prevention and early intervention of GDM, and highlighted the need for monitoring serum UA at 13-18 gestational weeks.PMID:34666165 | DOI:10.1016/j.diabet.2021.101293 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Yan Zhao Yongbo Zhao Kechen Fan Liping Jin Source Type: research

Short course corticosteroid treatment and closed-loop insulin delivery system: the experience of the DBLG1 pre-launch
Diabetes Metab. 2021 Oct 16:101294. doi: 10.1016/j.diabet.2021.101294. Online ahead of print.ABSTRACTNo abstract (brief report).PMID:34666166 | DOI:10.1016/j.diabet.2021.101294 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Coralie Amadou Sylvia Franc Erik Huneker Guillaume Charpentier Alfred Penfornis Source Type: research

The Progressive Uncoupling of Maternal Insulin Clearance and Insulin Sensitivity across Gestation
Diabetes Metab. 2021 Oct 16:101291. doi: 10.1016/j.diabet.2021.101291. Online ahead of print.NO ABSTRACTPMID:34666167 | DOI:10.1016/j.diabet.2021.101291 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 19, 2021 Category: Endocrinology Authors: Mireille van Poppel Ravi Retnakaran Source Type: research

Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
CONCLUSION: In our cohort, mMVC were not associated with cancer-related events, while history of cancer was significantly associated with cardiovascular death.PMID:34644608 | DOI:10.1016/j.diabet.2021.101289 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 13, 2021 Category: Endocrinology Authors: Evelyne Liuu Pierre-Jean Saulnier Elise Gand Gautier Defossez Am élie Jamet St éphanie Ragot Marc Paccalin Samy Hadjadj SURDIAGENE study group Source Type: research

Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
CONCLUSION: In our cohort, mMVC were not associated with cancer-related events, while history of cancer was significantly associated with cardiovascular death.PMID:34644608 | DOI:10.1016/j.diabet.2021.101289 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 13, 2021 Category: Endocrinology Authors: Evelyne Liuu Pierre-Jean Saulnier Elise Gand Gautier Defossez Am élie Jamet St éphanie Ragot Marc Paccalin Samy Hadjadj SURDIAGENE study group Source Type: research

Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
CONCLUSION: In our cohort, mMVC were not associated with cancer-related events, while history of cancer was significantly associated with cardiovascular death.PMID:34644608 | DOI:10.1016/j.diabet.2021.101289 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 13, 2021 Category: Endocrinology Authors: Evelyne Liuu Pierre-Jean Saulnier Elise Gand Gautier Defossez Am élie Jamet St éphanie Ragot Marc Paccalin Samy Hadjadj SURDIAGENE study group Source Type: research

Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
CONCLUSION: In our cohort, mMVC were not associated with cancer-related events, while history of cancer was significantly associated with cardiovascular death.PMID:34644608 | DOI:10.1016/j.diabet.2021.101289 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 13, 2021 Category: Endocrinology Authors: Evelyne Liuu Pierre-Jean Saulnier Elise Gand Gautier Defossez Am élie Jamet St éphanie Ragot Marc Paccalin Samy Hadjadj SURDIAGENE study group Source Type: research

Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
CONCLUSION: In our cohort, mMVC were not associated with cancer-related events, while history of cancer was significantly associated with cardiovascular death.PMID:34644608 | DOI:10.1016/j.diabet.2021.101289 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 13, 2021 Category: Endocrinology Authors: Evelyne Liuu Pierre-Jean Saulnier Elise Gand Gautier Defossez Am élie Jamet St éphanie Ragot Marc Paccalin Samy Hadjadj SURDIAGENE study group Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection
Diabetes Metab. 2021 Sep 28:101285. doi: 10.1016/j.diabet.2021.101285. Online ahead of print.ABSTRACTSodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluation of the diuretic effect is...
Source: Diabetes and Metabolism - October 1, 2021 Category: Endocrinology Authors: Pierre Delanaye Andre J Scheen Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Diabetes Metab. 2021 Sep 19:101284. doi: 10.1016/j.diabet.2021.101284. Online ahead of print.ABSTRACTAIM: Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.METHODS: We studied prospectively 82 patients with T2DM (51 without sta...
Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research

Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: a ten-year follow-up study
Diabetes Metab. 2021 Sep 18:101282. doi: 10.1016/j.diabet.2021.101282. Online ahead of print.ABSTRACTAIMS: To assess the impact of bariatric surgery on remission and relapse of type 2 diabetes mellitus (T2DM) at 10 years of follow-up and analyze predictive factors.MATERIALS AND METHODS: Eighty-eight obese subjects undergoing Roux-en-Y gastric bypass (RYGB) and 25 subjects assigned to medical therapy (MT) were evaluated every year for 10 years. T2DM remission was defined by the American Diabetes Association criteria.RESULTS: Body mass index (BMI), fasting glucose, and hemoglobin A1c (HbA1c) improved more markedly in RYGB th...
Source: Diabetes and Metabolism - September 21, 2021 Category: Endocrinology Authors: Diego Moriconi Maria Laura Manca Marco Anselmino Eleni Rebelos Rosario Bellini Stefano Taddei Ele Ferrannini Monica Nannipieri Source Type: research

Glycaemic variabilities: Key questions in pursuit of clarity
Diabetes Metab. 2021 Sep 18:101283. doi: 10.1016/j.diabet.2021.101283. Online ahead of print.ABSTRACTAfter years of intensive investigation, the definition of glycaemic variability remains unclear and the term variability in glucose homoeostasis might be more appropriate covering both short and long-term glycaemic variability. For the latter, we remain in the search of an accurate definition and related targets. Recent work leads us to consider that the within-subject variability of HbA1c calculated from consecutive determinations of HbA1c at regular time-intervals could be the most relevant index for assessing the long-te...
Source: Diabetes and Metabolism - September 21, 2021 Category: Endocrinology Authors: L Ouis Monnier David Owens Claude Colette Fabrice Bonnet Source Type: research

Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design
Diabetes Metab. 2021 Sep 17:101281. doi: 10.1016/j.diabet.2021.101281. Online ahead of print.ABSTRACTThe natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to conside...
Source: Diabetes and Metabolism - September 20, 2021 Category: Endocrinology Authors: Pierpaolo Pellicori Muthiah Vaduganathan O ão Pedro Ferreira Faiez Zannad Arun J Sanyal Source Type: research

Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design
Diabetes Metab. 2021 Sep 17:101281. doi: 10.1016/j.diabet.2021.101281. Online ahead of print.ABSTRACTThe natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to conside...
Source: Diabetes and Metabolism - September 20, 2021 Category: Endocrinology Authors: Pierpaolo Pellicori Muthiah Vaduganathan O ão Pedro Ferreira Faiez Zannad Arun J Sanyal Source Type: research

Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial
CONCLUSION: A short-term treatment with dapagliflozin may increase CRT as compared with equivalent glycemic control with glibenclamide.PMID:34537385 | DOI:10.1016/j.diabet.2021.101280 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 19, 2021 Category: Endocrinology Authors: Vicente Hidalgo Rodrigues Fernandes Fernando R P Chaves Alexandre A S Soares Ikaro Breder Sheila T Kimura-Medorima Daniel B Munhoz Riobaldo M R Cintra Jessica Cunha Breder Joaquim Barreto Wilson Nadruz Luiz Sergio F Carvalho Thiago Quinaglia Carlos E L Ar Source Type: research

Eye disorders other than diabetic retinopathy in patients with diabetes
CONCLUSION: Diabetes, beyond diabetic retinopathy, increases the risk of numerous eye disorders leading to low vision with implications for daily diabetes management. Even in the absence of clearly demonstrated benefit from glucose control in all eye conditions, achieving good glycaemic control and adherence to diabetes treatment will likely help avoid an additional risk of visual impairment in people with diabetes. In perspective, interesting findings suggesting a preventive effect of metformin use on age-related macular degeneration occurrence justify further studies.PMID:34534696 | DOI:10.1016/j.diabet.2021.101279 (Sour...
Source: Diabetes and Metabolism - September 17, 2021 Category: Endocrinology Authors: Sylvie Feldman-Billard B énédicte Dupas Source Type: research

Overweight and Risk of Type 2 Diabetes: A Prospective Chinese Twin Study
CONCLUSIONS: Our findings suggest that genetics and early-life environments might account for the observed overweight-T2DM association. Genetic correlation between BMI and T2DM further provides evidence for the influence of overlap genes on their association.PMID:34520837 | DOI:10.1016/j.diabet.2021.101278 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 14, 2021 Category: Endocrinology Authors: Yu'e Xi Wenjing Gao Ke Zheng Jun Lv Canqing Yu Shengfeng Wang Tao Huang Dianjianyi Sun Chunxiao Liao Yuanjie Pang Zengchang Pang Min Yu Hua Wang Xianping Wu Zhong Dong Fan Wu Guohong Jiang Xiaojie Wang Yu Liu Jian Deng Lin Lu Weihua Cao Liming Li Source Type: research

Overweight and Risk of Type 2 Diabetes: A Prospective Chinese Twin Study
CONCLUSIONS: Our findings suggest that genetics and early-life environments might account for the observed overweight-T2DM association. Genetic correlation between BMI and T2DM further provides evidence for the influence of overlap genes on their association.PMID:34520837 | DOI:10.1016/j.diabet.2021.101278 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 14, 2021 Category: Endocrinology Authors: Yu'e Xi Wenjing Gao Ke Zheng Jun Lv Canqing Yu Shengfeng Wang Tao Huang Dianjianyi Sun Chunxiao Liao Yuanjie Pang Zengchang Pang Min Yu Hua Wang Xianping Wu Zhong Dong Fan Wu Guohong Jiang Xiaojie Wang Yu Liu Jian Deng Lin Lu Weihua Cao Liming Li Source Type: research

Overweight and Risk of Type 2 Diabetes: A Prospective Chinese Twin Study
CONCLUSIONS: Our findings suggest that genetics and early-life environments might account for the observed overweight-T2DM association. Genetic correlation between BMI and T2DM further provides evidence for the influence of overlap genes on their association.PMID:34520837 | DOI:10.1016/j.diabet.2021.101278 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 14, 2021 Category: Endocrinology Authors: Yu'e Xi Wenjing Gao Ke Zheng Jun Lv Canqing Yu Shengfeng Wang Tao Huang Dianjianyi Sun Chunxiao Liao Yuanjie Pang Zengchang Pang Min Yu Hua Wang Xianping Wu Zhong Dong Fan Wu Guohong Jiang Xiaojie Wang Yu Liu Jian Deng Lin Lu Weihua Cao Liming Li Source Type: research

Overweight and Risk of Type 2 Diabetes: A Prospective Chinese Twin Study
CONCLUSIONS: Our findings suggest that genetics and early-life environments might account for the observed overweight-T2DM association. Genetic correlation between BMI and T2DM further provides evidence for the influence of overlap genes on their association.PMID:34520837 | DOI:10.1016/j.diabet.2021.101278 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 14, 2021 Category: Endocrinology Authors: Yu'e Xi Wenjing Gao Ke Zheng Jun Lv Canqing Yu Shengfeng Wang Tao Huang Dianjianyi Sun Chunxiao Liao Yuanjie Pang Zengchang Pang Min Yu Hua Wang Xianping Wu Zhong Dong Fan Wu Guohong Jiang Xiaojie Wang Yu Liu Jian Deng Lin Lu Weihua Cao Liming Li Source Type: research

Overweight and Risk of Type 2 Diabetes: A Prospective Chinese Twin Study
CONCLUSIONS: Our findings suggest that genetics and early-life environments might account for the observed overweight-T2DM association. Genetic correlation between BMI and T2DM further provides evidence for the influence of overlap genes on their association.PMID:34520837 | DOI:10.1016/j.diabet.2021.101278 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - September 14, 2021 Category: Endocrinology Authors: Yu'e Xi Wenjing Gao Ke Zheng Jun Lv Canqing Yu Shengfeng Wang Tao Huang Dianjianyi Sun Chunxiao Liao Yuanjie Pang Zengchang Pang Min Yu Hua Wang Xianping Wu Zhong Dong Fan Wu Guohong Jiang Xiaojie Wang Yu Liu Jian Deng Lin Lu Weihua Cao Liming Li Source Type: research

Lower trabecular bone score in type 2 diabetes mellitus: a role for fat mass and insulin resistance beyond hyperglycaemia
Diabetes Metab. 2021 Sep 10:101276. doi: 10.1016/j.diabet.2021.101276. Online ahead of print.ABSTRACTAIMS: To examine the clinical and biochemical determinants of trabecular bone score (TBS) in type 2 diabetes mellitus (T2DM) patients.METHODS: Cross-sectional observational study in 137 T2DM patients (49-85 years). Whole-body fat percentage was estimated using the relative fat mass (RFM) equation. Bone mineral density (BMD) and TBS were assessed using dual-energy X-ray absorptiometry and TBS iNsight Software respectively.RESULTS: T2DM patients showed significantly lower TBS values (P
Source: Diabetes and Metabolism - September 13, 2021 Category: Endocrinology Authors: Mar ía Hayón-Ponce Beatriz Garc ía-Fontana Mar ía Dolores Avilés-Pérez Sheila Gonz ález-Salvatierra Francisco And újar-Vera Enrique Moratalla-Aranda Manuel Mu ñoz-Torres Source Type: research